Evidence map›Paper›PMID 30079174›Full record

ArticleMedChemComm2018

A synthetic diphosphoinositol phosphate analogue of inositol trisphosphate.

Andrew M Riley, Judith Unterlass, Vera Konieczny, Colin W Taylor, Thomas Helleday, Barry V L Potter

Open access · hybridAbstract read
In one paragraph

Article in MedChemComm, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. New structural insights reveal an expanded reaction cycle for inositol pyrophosphate hydrolysis by human DIPP1.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  4. Review
  5. Both d- and l-Glucose Polyphosphates Mimic d-Journal of medicinal chemistry · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Andrew M RileyMedicinal Chemistry and Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, U.K.
Judith UnterlassScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, SE-171 21 Solna, Sweden.
Vera KoniecznyDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK.
Colin W TaylorDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK.
Thomas HelledayScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, SE-171 21 Solna, Sweden.
Barry V L PotterMedicinal Chemistry and Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, U.K.
Science for Life Laboratory · SEUniversity of Cambridge · GBUniversity of Oxford · GB

Funding

Wellcome Trust 101010Wellcome Trust 101844
6 · The paper itself

Abstract

Diphosphoinositol phosphates (PP-InsPs) are inositol phosphates (InsPs) that contain PP (diphosphate) groups. Converting a phosphate group in an InsP into a diphosphate has been reported to enhance affinity for some binding proteins. We synthesised 1-PP-Ins(4,5)P

Identifiers

PMID30079174
PMCPMC6071853
OpenAlexW2807163909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.